InnerScope Hearing Technologies, Inc.

InnerScope Hearing Technologies, Inc. provides hearing aids and its hearable, and wearable personal sound amplifier products to retail hearing aid dispensing community. The company engages in the provision of manufacturing and direct-to-consumer distribution/retail of hearing aids, personal sound amplifier products, hearing related treatment therapies, doctor-formulated dietary hearing supplements, and proprietary CDB oil for treating tinnitus. It also owns and operates 11 audiological and retail hearing device clinics; and offers business to business SaaS based patient management system software program. The company was formerly known as Innerscope Advertising Agency, Inc. and changed its name to InnerScope Hearing Technologies, Inc. in August 2017. InnerScope Hearing Technologies, Inc. was incorporated in 2012 and is headquartered in Roseville, California.

InnerScope Hearing Technologies, Inc. trades as INND on OTC. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in USD.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $34,694 of revenue and -$174,652 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

InnerScope Hearing Technologies, Inc. can be compared against peers such as Aida Pharmaceuticals, Inc., Better Therapeutics, Inc., Inyx, Inc., Lancer Orthodontics, Inc., MJ Holdings, Inc., MedSmart Group Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $306, beta of 1.45, and return on equity of -0.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

INND currently shows total debt of $1.77M and beta of 1.45. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SC 13G/A (2024-12-31 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.innd.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.